Most Recent
Sanofi slams judge’s harm assessment in denying injector pen injunction
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
ABC demands details from Michelle Guthrie before mediation in unfair sacking case
The ABC has called for a "clearer articulation" of former managing director Michelle Guthrie's unfair sacking claims against the broadcaster ahead of court-ordered mediation.
Aerocare loses appeal of split shifts ruling
Aviation services company Aerocare has lost its appeal of a Fair Work Commission decision that shot down an enterprise agreement forcing employees to work split shifts.
Deep Investments’ case over $10M in share trading losses shut down
An appeals court has shut down a case brought by investment adviser Deep Investments against a solicitor and six others over $10 million in alleged share trading losses, saying the proceedings were an abuse of process.
Full Court puts injector pen patent appeal on fast track
The Full Federal Court has expedited an appeal filed Christmas Eve by Sanofi-Aventis of a ruling that denied its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
Toxic foam class action not time-barred, court hears
The applicants in a class action over exposure to allegedly toxic foam used on a government military base have struck back at the Commonwealth of Australia's argument that their claims were filed too late.
Sandoz appeals loss in 15-year battle over Lexapro patent
Generic drug maker Sandoz is challenging a ruling that it infringed a patent behind Lundbeck's blockbuster antidepressant Lexapro, reviving a 15-year fight over the lucrative intellectual property.
Sanofi takes another stab at injunction in injector pen patent case
French pharmaceutical giant Sanofi has appealed a judge's ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
IOOF says APRA should be able to state its case after 3-year probe
A barrister for two units of embattled wealth manager IOOF and three senior company executives facing claims by APRA have criticised the regulator for filing a broad concise statement and no statement of claim after a three-year investigation.
NSW Ports pans ACCC for ‘vague’ competition case
NSW Ports has criticised the Australian Competition and Consumer Commission for expecting the company to file a defence to the regulator's allegations of anti-competitive conduct from a concise statement it panned as "vague".